Details of the Drug

General Information of Drug (ID: DMMQ6VT)

Drug Name

Leronlimab

Synonyms

PRO 140

Indication

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antiviral Agents

Drug Type

Monoclonal antibody

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 24.4 mgday/L [2]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 6.1 mg/L [2]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 32 h [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 3.4 days [2]
Metabolism: The drug is metabolized via proteolytic enzymes []

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HUMAN C-C chemokine receptor 5 (CCR5)	TTH91NV	CCR5_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04343651) Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
2	Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis. 2010 May 15;201(10):1481-7. doi: 10.1086/652190.
3	Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19